By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Argenx 

Willemstraat 5

Breda    4811 AH  The Nederlands
Phone: 31-0-10-763-030-488 Fax: n/a


SEARCH JOBS

argenx a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.

YEAR FOUNDED:

2008

LEADERSHIP:

CEO: Tim Van Hauwermeiren

CFO: Eric Castaldi

CSO: Hans de Haard

CDO: Torsten Dreier

CMO: Nicolas Leupin

JOBS:

Please click here for Argenx job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email: nfo@argenx.com
Ownership: Private

Web Site: Argenx
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
Argenx Announces Full Exercise Of Underwriters' Option To Purchase Additional ADSs 5/19/2017 7:33:53 AM
Argenx Raises Approximately $100 Million Gross Proceeds With NASDAQ IPO 5/18/2017 11:00:38 AM
Argenx Announces Size Of Initial Public Offering In The United States Increased To 5 Million ADSs 5/16/2017 10:48:10 AM
Argenx Announces Launch Of Proposed Initial Public Offering In The United States 5/8/2017 10:52:10 AM
Argenx Reaches 50% Enrollment In Phase II Clinical Trial Of ARGX-113 In Myasthenia Gravis 5/4/2017 11:41:02 AM
Argenx Reports First Quarter 2017 Financial Results And Provides Business Update 5/3/2017 11:04:56 AM
Argenx Announces Results Of Annual General Meeting 2017 4/26/2017 10:46:20 AM
Argenx Files Registration Statement For A Proposed Public Offering In The United States 4/24/2017 11:11:54 AM
Argenx Launches Phase II Study Of ARGX-110 As A Monotherapy In Relapsed/Refractory CTCL Patients 4/12/2017 10:46:27 AM
Staten Biotech Exercises Option To Develop Therapeutic SIMPLE Antibody For Dyslipidemia From Argenx 3/6/2017 8:59:00 AM
1234
//-->